The Nordic Region consists of Denmark, Norway, Sweden, Finland and Iceland.
The combined population is more than 27 million in 2015.
Nordic Capability
The Nordic countries have an excellent reputation of running first-class clinical trials in all phases of drug research and development.
In addition, several university hospitals are dedicated Centres of Excellence – e.g. for Phase I trials and Translational Research.
Nordic Pharma & Biotech
The Nordic countries have been very active in the pharmaceutical industry for generations, seeing such major successes as Astra (AstraZeneca), Novo Nordisk, Nycomed (Takeda), Lundbeck, LEO Pharma, Pharmacia (Pfizer). In addition there is a plethora of smaller biotech companies established here – including well-known successes like Genmab and Bavarian Nordic. In fact, pharmaceuticals are Denmark’s #1 export: 11+ billion euros ($12.5 billion), accounting for 12 percent for 2015.
Government Support
Research and innovation in the pharmaceutical sector is highly prioritized by Nordic authorities who offer support connecting business to academia providing unique access and opportunities. These features make the ”small” Nordics a very attractive region to invest in research and development in life-science.
Quick Facts
Population
Denmark 5.7 million
Finland 5.5 million
Norway 5.2 million
Sweden 9.7 million
Languages
Checkpoint North can navigate you through all Nordic languages
Academia
There are 23 highly skilled and internationally recognised University Hospitals in the Nordics that we can connect you to.